Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins

Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins

US Patent 5783181 · Granted Jul 21, 1998

Estimated economic value: $31,443,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapy with apilimod and glutamatergic agents2024
Bicyclic bromodomain inhibitors2022
Combination therapy with apilimod and glutamatergic agents2022
Substituted bicyclic compounds as bromodomain inhibitors2021
Bicyclic bromodomain inhibitors2020
Combination therapy with apilimod and glutamatergic agents2020
Inhibitors of bromodomains2019
Substituted bicyclic compounds as bromodomain inhibitors2019
Substituted bicyclic compounds as bromodomain inhibitors2019
Bicyclic bromodomain inhibitors2018
Heterocyclic compounds as bromodomain inhibitors2018
Biaryl derivatives as bromodomain inhibitors2017